January 27, 2023 10:35 AM ESTUpdated 02:25 PM
People
R&D

Dutch biotech starts liq­ui­da­tion af­ter end­ing PhI­II in GVHD

Kyle LaHucik

Senior Reporter

A 13-year-old Dutch biotech is go­ing through a liq­ui­da­tion process af­ter an un­ex­pect­ed end to its Phase III tri­al test­ing whether its com­bi­na­tion of two …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times